Exegenesis Bio gets FDA nod to begin human testing of macular degeneration treatment

The company, which has its U.S. headquarters at the Spring House Innovation Park, expects to begin enrolling patients in its Phase 1 clinical trial during the first quarter of this year.

Previous Visura Technologies raises $4 million to expand commercial efforts for its imaging probe
Next Celebrity chef targets Birmingham neighborhoods for restaurant expansion